Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
about
Future pharmacological treatments for substance use disordersNeuropharmacology of alcohol addictionBaclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581]Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulationGABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidenceUpdate on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validityMapping a barbiturate withdrawal locus to a 0.44 Mb interval and analysis of a novel null mutant identify a role for Kcnj9 (GIRK3) in withdrawal from pentobarbital, zolpidem, and ethanol.The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.GABA(A) receptors in the dorsal raphé nucleus of mice: escalation of aggression after alcohol consumption.Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinkingA preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption.Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: a longitudinal perfusion fMRI study.Comparison of the effect of the GABAΒ receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats.GABAB receptor activation attenuates the stimulant but not mesolimbic dopamine response to ethanol in FAST mice.GABAergic modulation of binge-like ethanol intake in C57BL/6J miceR(+)-Baclofen, but Not S(-)-Baclofen, Alters Alcohol Self-Administration in Alcohol-Preferring Rats.Acute interaction of baclofen in combination with alcohol in heavy social drinkersAttenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABA, but not a GABA, receptor agonist.Identification and management of alcohol withdrawal syndromeAcute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study.Increased Ethanol Consumption Following Chronic Psychosocial Stress: Do Oxytocin and Baclofen Hold any Therapeutic Promise?Site-specific microinjection of baclofen into the anterior ventral tegmental area reduces binge-like ethanol intake in male C57BL/6J mice.Development of pharmacotherapies for drug addiction: a Rosetta stone approach.Discovering genes involved in alcohol dependence and other alcohol responses: role of animal models.Early ethanol and water intake: choice mechanism and total fluid regulation operate in parallel in male alcohol preferring (P) and both Wistar and Sprague Dawley rats.Pharmacotherapy of acute alcoholic hepatitis in clinical practice.Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.Synaptic targets: Chronic alcohol actions.A selective ALDH-2 inhibitor reduces anxiety in rats.Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal.KCTD12 modulation of GABA(B) receptor function.Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons.GABA(B) receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area.Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model.Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.Suppressing Effect of Baclofen on Multiple Alcohol-Related Behaviors in Laboratory AnimalsA Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder
P2860
Q22242633-68AD3EC1-34A6-4CDD-8F3E-8BA271371267Q22251110-59193DF8-98C2-4D4D-AF3A-F06E9B7C4141Q24799720-7836AAF4-35FF-419A-A4C2-AF0A731C43E4Q26853630-3ECC7AF1-16EF-492A-9234-5FA3CA6E6ADCQ27026530-F76FAE15-7C87-406C-B20B-C3FE0A1447C0Q30440516-A719BDD9-5856-4E36-8024-DAD51C476591Q30447847-4FB527AC-8407-4C5C-8035-BBCE6CEDACEBQ30492936-61970FE4-819A-426F-8476-42711D34F475Q33757216-4515FD11-C818-4C1F-A153-9AB035791DABQ34356376-41643DC0-4847-422C-8E3F-56AD8F683AD9Q34415017-44C8B2E0-7E3F-4D9F-81CD-70E82050E692Q34785056-470F9FD3-397D-4014-BA52-3692CBC0E08DQ35039864-0F6ADAA2-5767-46E5-91ED-C5B479045398Q35947830-886D0BDD-D13B-456D-81C9-893D0EDD6F43Q36095127-8725D6C2-B3C0-4B7E-B5C0-65E76F705F8DQ36405967-8298F7C0-EA3E-4E77-A0A0-8316B143CC5AQ36672572-2A3F1DA5-0493-40C5-B40D-61BFC6E0C329Q36805735-5C0D8A75-5648-4EB4-9115-1E0346799E24Q37060525-21369191-22F5-430E-8A29-85BE3484D7CCQ37087286-B9BB9F53-FFBF-4E8A-9B61-B4751D6A1176Q37161994-02DCA92D-E0D5-4D2C-9A66-2AE16F8EAE74Q37163680-7FF821DB-3CD8-41DA-B43F-7B0F7F92FB1EQ37309654-5E63699C-3FED-4DB1-AA84-8E2655C8EAFAQ37318993-5D3A5EC5-44CD-49DF-934C-9B5D448225CDQ37383571-11F69617-B6E6-4ECB-981E-FE892376318DQ37386396-9D61EE0D-D888-404D-99C2-98163BE35E7CQ37398597-B3251485-1697-4E6E-9D7F-706EC442C071Q37617944-2C56E979-CF65-4368-9FC7-BB0C62E81618Q38718932-AA64B56A-859A-4CDE-A717-A9FE8AD12709Q39096987-5DD6F784-A9B0-4244-BDB1-516542C9EC3CQ40195959-E9359515-35EF-4441-AC16-F1A988737E8CQ40231786-E197FA91-6502-47C4-9C4E-D9EACCDA6046Q41001603-BA806C23-C900-412E-A992-502274AEFB49Q41844916-83DD292E-0CAF-467D-BE27-43A65B603ECBQ43261524-2A1BCE72-AA7A-4002-88B5-985EA7011C2EQ44499313-25313B0D-9A4B-4556-935D-BE3EFE0051FFQ52893441-6DC9DC97-66B0-453C-B814-78EB27F5DF4CQ57490270-C1256198-CE81-41A2-B7C2-08A017B122AAQ59127665-68F4DE12-40EC-42AF-81E0-FAD7C081D803
P2860
Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@en
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@nl
type
label
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@en
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@nl
prefLabel
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@en
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@nl
P2093
P2860
P1476
Ability of baclofen in reducin ...... rity: I--Preclinical evidence.
@en
P2093
Addolorato G
P2860
P356
10.1111/J.1530-0277.2000.TB04554.X
P577
2000-01-01T00:00:00Z